Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO Nasal Spray from Hikma Pharmaceuticals
| HCI Stock | USD 121.93 0.41 0.34% |
Under 62% of HCI's investor base is looking to short. The analysis of the overall prospects from investing in HCI Group suggests that many traders are, at the present time, alarmed. HCI's investing sentiment shows overall attitude of investors towards HCI Group.
HCI |
Alongside over-the-counter NARCAN Nasal Spray 4 mg, prescription KLOXXADO Nasal Spray 8 mg will expand Emergents ability to distribute...
Read at globenewswire.com
 |
HCI Fundamental Analysis
We analyze HCI's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCI based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Five Year Return
Five Year Return Comparative Analysis
HCI is currently under evaluation in five year return category among its peers. Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
HCI Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with HCI stock to make a market-neutral strategy. Peer analysis of HCI could also be used in its relative valuation, which is a method of valuing HCI by comparing valuation metrics with similar companies.
Peers
HCI Related Equities
| GBLI | Global Indemnity | 3.99 | ||||
| SIGI | Selective Insurance | 2.42 | ||||
| KINS | Kingstone Companies | 2.35 | ||||
| DGICA | Donegal Group | 1.58 | ||||
| HRTG | Heritage Insurance | 1.19 | ||||
| ARGO-PA | Argo Group | 0.12 | ||||
| DGICB | Donegal Group | 0.36 | ||||
| SIGIP | Selective Insurance | 0.73 | ||||
| HMN | Horace Mann | 0.82 | ||||
| UVE | Universal Insurance | 0.92 | ||||
| KMPR | Kemper | 1.34 | ||||
| NODK | NI Holdings | 1.69 | ||||
| UFCS | United Fire | 1.74 |
Complementary Tools for HCI Stock analysis
When running HCI's price analysis, check to measure HCI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCI is operating at the current time. Most of HCI's value examination focuses on studying past and present price action to predict the probability of HCI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCI's price. Additionally, you may evaluate how the addition of HCI to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |